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ABSTRACT  
Objective. To compare the risk for major adverse cardiovascular events (MACE) in RA 
patients treated with tocilizumab versus the tumor necrosis factor inhibitor etanercept. 
Methods. This randomized, open-label, parallel-group trial enrolled patients with active 
seropositive RA (N=3080), inadequate responses to conventional synthetic disease-
modifying antirheumatic drugs, and at least one cardiovascular risk factor. Patients were 
randomly assigned 1:1 to open-label tocilizumab 8 mg/kg/month or etanercept 50 mg/week 
and followed up for an average of 3.2 years. The primary end point was comparison of time-
to-first MACE. The trial was powered to exclude a 1.8 or higher relative hazard of MACE for 
tocilizumab versus etanercept. 
Results. By week 4, serum low-density lipoprotein cholesterol, high-density lipoprotein 
cholesterol, and triglyceride levels were 11.1%, 5.7%, and 13.6% higher, respectively, for 
patients allocated to tocilizumab compared with etanercept (all P<.001). During follow-up, 
83 MACE occurred in the tocilizumab group compared with 78 in the etanercept group. The 
estimated hazard of MACE for tocilizumab relative to etanercept was 1.05 (95% confidence 
interval=0.77, 1.43).  Result were similar in sensitivity analyses and the on-treatment 
analysis.  Adverse events that occurred more frequently in the tocilizumab group included 
serious infection and gastrointestinal perforation. 
Conclusion. The trial, which provides insights into the cardiovascular safety of tocilizumab 
versus etanercept, excluded a relative risk for MACE of 1.43 or higher. This result should be 
interpreted in the context of the clinical efficacy and the non-cardiovascular safety of 
tocilizumab.  
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Trial Registration.  ClinicalTrials.gov identifier NCT01331837 
 
Treatment with tocilizumab, a fully humanized monoclonal antibody targeting interleukin-6 
receptor alpha (IL-6α), provides a reduction in the signs and symptoms of rheumatoid 
arthritis (RA) and a marked reduction in the levels of circulating inflammatory markers (1, 2). 
In parallel, treatment-associated increases in circulating lipid concentrations have been 
observed, with average increases in low-density lipoprotein cholesterol (LDL-C) of 12% to 
20% noted across pivotal clinical trials (3). In a recent meta-analysis (4), the odds of having 
elevated LDL-C levels, defined as >130 mg/dL, was 4.8-fold higher in tocilizumab-treated 
patients with RA than in patients treated with placebo. High-density lipoprotein cholesterol 
(HDL-C) also tended to increase with tocilizumab treatment because the odds of having high 
HDL-C, defined as >60 mg/dL, were more than 2-fold higher in tocilizumab-treated patients 
than in placebo-treated patients in the same meta-analysis. Considering that RA is 
associated with a greater burden of atherosclerosis (5, 6) and that deaths from 
atherosclerotic events and cardiovascular disease (CVD) are higher in patients with RA than 
in those without (7, 8), treatment-associated increased concentrations of lipids with 
atherogenic potential have called into question the CVD risk-to-benefit ratio of tocilizumab 
in RA. 
 
In the MEASURE trial, designed to evaluate the effects of tocilizumab therapy on CVD 
biomarkers, concentrations of the more atherogenic circulating small LDL particles and 
oxidized LDL did not increase with tocilizumab treatment and were similar to those 
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observed with placebo, despite an increase in overall LDL-C (9). At the same time, 
tocilizumab was associated with greater reductions, relative to placebo, in potentially 
proatherogenic factors, such as HDL-associated serum amyloid A, secretory phospholipase 
A2, and lipoprotein(a). However, whether such changes affect CVD event risk has not been 
evaluated in a clinical trial.  
 
Given the increased levels of circulating total cholesterol, LDL-C, and triglycerides caused by 
tocilizumab, the ENTRACTE trial was designed to compare the risk for major adverse 
cardiovascular events (MACE) in patients with RA treated with tocilizumab and the risk in 
those treated with the tumor necrosis factor (TNF) inhibitor etanercept, a biologic standard-
of-care treatment for RA with a mechanism of action different from that of tocilizumab that 
has minimal effects on atherogenic lipids. Patients with high RA disease activity and baseline 
CVD risk factors were targeted. 
   
Methods 
Trial oversight and design. ENTRACTE (ClinicalTrials.gov number, NCT01331837) was a 2-
arm, randomized, open-label, parallel-group, multicenter trial designed to address the 
cardiovascular (CV) safety of tocilizumab versus that of etanercept in patients with RA. The 
trial was designed and executed as a postmarketing requirement of the US Food and Drug 
Administration. The sponsor was responsible for the study design, in collaboration with an 
external 6-member multidisciplinary steering committee who also supervised trial conduct; 
provided advice on scientific issues; was involved in the collection, analysis, and 
interpretation of data; wrote the manuscript; and approved the decision to submit the 
manuscript for publication. All authors were involved in analysis or interpretation of the 
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data, and all authors made the decision to submit the manuscript for publication. The 
authors vouch for the accuracy and completeness of the data and for adherence to the trial 
protocol. The corresponding author had full access to all study data and had final 
responsibility for the decision to submit the paper for publication. The trial was approved by 
local institutional review boards/ethics committees. All patients provided written informed 
consent in accordance with the Declaration of Helsinki. 
 
Patient population. Eligible patients had RA, based on the American College of 
Rheumatology 1987 criteria (10), of ≥6 months’ duration, inadequate response to a previous 
conventional synthetic disease-modifying antirheumatic drug (csDMARD) or anti-TNF 
treatment, seropositivity for rheumatoid factor (RF) or anti–cyclic citrullinated protein (anti-
CCP), ≥8 swollen joints (66 joint count) and 8 tender joints (68 joint count) at screening, and 
C-reactive protein (CRP) >0.3 mg/dL. Additionally, patients were required to be ≥50 years 
old and to have ≥1 traditional CVD risk factors, extra-articular RA manifestations (including 
subcutaneous rheumatoid nodules, secondary Sjogren syndrome, serositis, rheumatoid lung 
disease/ interstitial lung disease, vasculitis, inflammatory peripheral neuropathy, or scleritis/ 
episcleritis), or history of a CVD event, which included prior MI, CVA, coronary 
revascularization procedure, hospitalization for unstable angina, symptomatic carotid artery 
disease, peripheral arterial disease, or abdominal aortic aneurysm. Patients with moderate 
or severe heart failure were excluded due to the contraindication of randomization to a TNF 
inhibitor.  Those who previously received treatment with a non-TNF biologic or etanercept 
were excluded, and enrollment of those who previously received treatment with non-
etanercept TNF inhibitors was restricted to 20%.  Individuals with a history of diverticulitis, 
diverticulosis requiring antibiotic treatment or chronic ulcerative lower gastrointestinal 
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disease such as Crohn’s disease, ulcerative colitis or other symptomatic lower 
gastrointestinal conditions that might predispose to perforations were excluded.  Additional 
inclusion and exclusion criteria are included in the Supplementary Appendix. 
 
Intervention, randomization, and blinding. Patients were randomly assigned using an 
interactive voice recording system (IVRS) 1:1 to either intravenous tocilizumab (8 mg/kg 
every 4 weeks) or subcutaneous etanercept (50 mg weekly), with or without background 
csDMARD(s). A pre-allocated blocked randomization schedule was implemented using a 
block size of 4 and was stratified according to previous exposure to anti-TNF therapy and 
history of CVD events. The random allocation sequence was generated by an independent 
vendor who managed the IVRS. Patients were enrolled by study site personnel and 
randomly assigned using the IVRS. Tocilizumab was administered at the study site, whereas 
etanercept was self-administered at home. The trial was open label at the study site but 
blinded to the sponsor. Site monitoring was independent of the sponsor, and data on 
treatment allocation was not divulged to the sponsor by monitors. An independent data 
monitoring committee reviewed unblinded data and monitored safety. 
 
Study visits. On-site study visits occurred monthly for tocilizumab-treated patients and 
every 3 months for etanercept-treated patients during years 1-3 and every 6 months during 
years 4-5. Enrollees could withdraw from active treatment at any time; crossover was 
discouraged, however, and patients who withdrew from treatment were encouraged to 
continue to be monitored for ongoing CVD and safety assessments. The trial commenced on 
August 2, 2011, and concluded on March 25, 2016.  
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End points and safety assessments. The prespecified primary end point was time to first 
occurrence of MACE, consisting of CV death, nonfatal myocardial infarction (MI), and 
nonfatal stroke (of any type). Undetermined causes of death were classified as MACE 
according to the Standardized Definitions of End Points in Clinical Trials (11). A secondary 
end point was time to first occurrence of an expanded composite end point, consisting of 
MACE + non-elective coronary revascularization procedures and hospitalization for unstable 
angina. Other secondary end points were all-cause mortality and time to first occurrence of 
each of the individual components of MACE. Exploratory end points included hospitalized 
heart failure (HHF) and MACE + HHF. 
 
CVD events and serious adverse events (SAEs) were assessed monthly throughout the trial, 
either on site or through a telephone call using an interactive voice response system. Any 
affirmative responses resulted in an alert for the site to contact the patient for additional 
detail on the possible adverse event (AE) or SAE. All potential end point events were 
adjudicated by a blinded independent CVD Events Adjudication Committee.  In the 
circumstance that the event was adjudicated as not a confirmed event, the patient was still 
considered at risk for a first event.  No efficacy data were assessed.  
 
Laboratory assessments. Peripheral blood was collected at 1 month and 3 months following 
randomization, every 3 months until year 3, and every 6 months from year 4 onward. 
Nonfasting total cholesterol, triglyceride, HDL-C, and LDL-C levels were measured by Roche 
(Basel, Switzerland)–BMD methodology, RF was measured by Roche Tina-quant 
immunoturbidimetric assay, anti-CCP was measured by enzyme-linked immunosorbent 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
assay, hemoglobin A1C was measured by Bio-Rad (Hercules, CA) high-performance liquid 
chromatography, and CRP was measured by Roche Tina-quant immunoturbidimetric assay. 
 
Statistical analysis. The primary objective of this trial was to provide a screening evaluation 
of cardiovascular safety by addressing whether a hazard ratio (HR) of 1.8 for MACE could be 
ruled out in the comparison between tocilizumab and etanercept. This would be achieved in 
a 131-event trial by an estimated HR ≤1.278, which would occur with 92% probability if the 
true HR were 1. The primary analysis of the MACE primary end point and of all secondary 
and exploratory time-to-event end points was based on a stratified Cox proportional 
hazards model using the intention-to-treat (ITT) population. Treatment arm was included as 
a covariate in the model, and the analysis was stratified by previous exposure to anti-TNF 
therapy and history of CVD events.  For the “on treatment” analyses, exposure time was 
truncated at 28 days after the last dose of randomized treatment unless a new biologic was 
started during that period.  In this case, exposure time was truncated at the date of the 
initiation of the new biologic. 
 
In many previous CV safety trials conducted in settings such as the evaluation of anti-
diabetes agents, obesity therapies, and cyclooxygenase-2 inhibitors and other nonsteroidal 
anti-inflammatory drugs in osteoarthritis and RA, a definitive evaluation of CV safety 
typically has required ruling out a noninferiority margin for the HR of MACE in the range of 
1.30 to 1.33. In those settings, ruling out much larger increases in the range of 1.8 to 2.0 has 
provided a screening evaluation for CV safety (12, 13). The design of ENTRACTE was 
consistent with this screening evaluation. Its primary objective, as stated, was to address 
whether a possible true HR of 1.8 could be ruled out (achieved when the upper limit of the 
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95% CI < 1.8). If that were to be achieved, then, in a nested manner preserving the 
experimental alpha level of a traditional 2.5% false positive error rate, a conclusion of 
“noninferiority of tocilizumab to etanercept” could be formally established if a possible true 
HR of 1.3 could be ruled out (achieved when the upper limit of the 95% CI < 1.3), where this 
would be achieved in a 131-event trial by an estimated HR ≤0.923 (or in a 161-event trial by 
an estimated HR ≤0.954). The corresponding sample size was n=1540 per treatment arm.  
Non-CVD safety events were assessed in the on-treatment safety population.  
 
Results 
A total of 3080 patients with RA were enrolled; 1538 were randomly assigned to the 
tocilizumab arm and 1542 were randomly assigned to the etanercept arm. The tocilizumab 
and etanercept arms contributed 4900 and 4891 ITT patient-years, respectively. The 
disposition of patients through the trial is depicted in Figure 1. Over an average follow-up 
time of 3.2 years, 2957 patients (96%) completed the trial with a full assessment of CVD 
events. Excluding those who died during follow-up, there were 26 patients in the 
tocilizumab group and 33 patients in the etanercept group without a full assessment of CVD 
events. Early discontinuation of randomized treatment occurred in 361 of 1542 (23%) 
etanercept-treated patients and 401 of 1538 (26%) tocilizumab-treated patients, 
representing 518.5 and 655.2 patient-years, respectively.  Etanercept-to-tocilizumab and 
tocilizumab-to-etanercept crossover occurred equally in 1% of enrollees in each arm.  
 
Baseline characteristics are summarized in Table 1 according to randomized treatment 
assignment. Characteristics were balanced across the treatment arms and reflected a 
population selected for having severe/active RA and being at high risk for CVD events. 
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Following initiation of study treatment, the tocilizumab group had a median 11.1% greater 
increase in LDL-C level compared with the etanercept group, 5.4% greater increase in HDL-C 
level, and 13.6% greater increase in triglyceride level at 4 weeks (all P<.001). These effects 
persisted over time (Figure 2).   
 
One hundred sixty-one patients experienced primary MACE events, 78 in the etanercept 
arm and 83 in the tocilizumab arm. Although the trial was designed for 131 events, 30 
additional events accrued because of inherent imprecision in identifying the proper timing 
of the data lock; this was further complicated by the lag time between identification and 
adjudication of possible events. In a comparison of tocilizumab with etanercept, the ITT HR 
for the primary end point of MACE that included undetermined cause of death was 1.05 
(95% confidence interval [CI], 0.77–1.43) (Table 2) (Kaplan-Meier plots for the primary end 
point are included in Supplementary Figure S1 in the Supplementary Appendix). The 
estimated HR was similar in sensitivity analyses using alternative classifications of MACE and 
in the analysis restricted to the period when patients were actually receiving the treatment 
to which they were assigned.  The estimated HR for tocilizumab versus etanercept for the 
secondary end points provided in Table 2 ranged from 0.89 for non-fatal MI (95% CI 0.54–
1.49) to 1.55 for all stroke types (95% CI 0.83–2.90). For fatal and nonfatal stroke, 26 events 
occurred in the tocilizumab group compared with 16 events in the etanercept group.  The 
HRs for cardiovascular death and death from any cause for the tocilizumab versus 
etanercept groups were 1.03 and 0.99, respectively. 
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Non-CVD AEs were common in both groups, but the rate was higher in the tocilizumab arm 
than in the etanercept arm (Table 3). However, neither AEs leading to discontinuation of 
study drug nor SAEs were meaningfully higher in the tocilizumab arm than in the etanercept 
arm. Infections (any infections and serious infections) were higher in the tocilizumab arm 
than in the etanercept arm. Eight confirmed gastrointestinal perforation events occurred in 
the tocilizumab arm compared with 1 event in the etanercept arm. Rates of malignancy, 
hypersensitivity events, serious bleeding events, and serious hepatic events were not 
meaningfully higher in the tocilizumab arm than in the etanercept arm, and no 
demyelinating events occurred. 
 
Discussion 
The primary aim of the ENTRACTE trial was to determine whether a relative risk for MACE of 
1.8 or higher for tocilizumab versus etanercept could be ruled out. The trial, which provides 
screening insights into the CVD safety of tocilizumab compared with etanercept, excluded a 
relative risk for MACE of 1.43 or higher in the ITT population. Similar estimates regarding 
CVD safety were obtained when the analysis was restricted to events that occurred while 
patients were still receiving randomized treatment and regarding multiple secondary and 
exploratory outcomes, with the exception of stroke and HHF.  
 
Macrophage-derived inflammatory cytokines, including IL-6, TNF-α, and IL-1β, are 
upregulated in RA and are targets for effective treatment of the signs and symptoms of the 
disease (14). Multiple studies support a role for IL-6 as a key contributor to atherogenesis, 
plaque destabilization, and atherothrombosis (15-18).  Similar to IL-6 levels, higher TNF-α 
levels have been linked to future CVD events (19), and TNF knockout or treatment with TNF 
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inhibitors was associated with a reduction in the burden of atherosclerosis in 
atherosclerosis-prone mice (20, 21). Moreover, a growing body of evidence from 
observational registries of TNF inhibitor–treated patients with RA suggests that CVD events 
are lower with TNF inhibitor treatment (22), an effect that may depend on clinical response 
(23). However, whether this effect is unique to TNF inhibitors as a class or extends to 
targeted immunomodulators with different mechanisms of action is unknown.  In a recent 
analysis of Medicare and insurance claims beneficiaries(24), Xie et al reported a relative 
hazard of MACE for etanercept vs. tocilizumab of 1.10 (95% CI=0.80, 1.51).  In a separate 
analysis of Medicare and private insurance claims (25), Kim et al also reported a lower but 
non-significant hazard of hospitalization for myocardial infarction or stroke for those 
prescribed tocilizumab compared to a combined TNF inhibitor group [HR=0.84 (95% CI=0.56, 
1.26)].  However, given the non-randomized treatment allocation and retrospective design, 
a randomized clinical trial, such as ENTRACTE, is needed to more accurately estimate the 
true relative risk between the treatments.  Additionally, the concept that cytokine inhibition 
may have antiatherogenic or antithrombotic effects, or both, on conditions other than RA is 
supported by the recently published Canakinumab Anti-inflammatory Thrombosis Outcomes 
Study, in which anti–IL-1β treatment of patients who previously experienced MI and 
elevated CRP levels was associated with a 15% reduction, compared with placebo, in the risk 
for MACE over 48 months (26).   
 
 On a molecular level, IL-6 inhibition differs from TNF inhibition in several pathways 
involved in lipid metabolism. RA is associated with LDL hypercatabolism, an effect that in 1 
study diminished with tocilizumab treatment, resulting in higher LDL-C levels (27). 
Additionally, tocilizumab was found to decrease IL-6–induced expression of the LDL receptor 
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(LDLr) on cultured hepatocytes, an effect not observed with the TNF inhibitor adalimumab 
(28). Such downregulation of LDLr on hepatocytes and other LDLr-expressing cells would be 
expected to result in higher circulating LDL levels. In the same study, tocilizumab treatment 
was associated with higher postprandial triglyceride levels and a delayed triglyceride peak 
after oral fat loading, suggesting attenuation of IL-6–induced lipolysis (28). The exact 
mechanism of tocilizumab-associated increases in levels of circulating triglycerides, 
however, is unclear. Perhaps more important is whether these tocilizumab-associated 
changes in lipid metabolism translate to actual CVD risk over time. Based on the findings of 
ENTRACTE, CVD risk on tocilizumab does not appear to be markedly increased compared 
with that on etanercept, at least within the first several years after therapy initiation, yet we 
cannot rule out a difference in relative hazard smaller than 1.43 given the width of the 
resulting CI for MACE.   The certainty around the relative differences between tocilizumab 
and etanercept for the secondary and exploratory outcomes, particularly for stroke and 
HHF, was lower, largely driven by the overall infrequency of these outcomes.   Given this 
infrequency, an even larger trial than ENTRACTE would be needed to stringently explore 
comparative differences on any one of the secondary outcomes.  
 
ENTRACTE has a number of notable strengths and limitations. Among the strengths, the 
retention rate for assessment of CVD events was very high (96%), and the unintended 
crossover rate was low (1%), both of which are indicators of a well-executed safety trial 
designed to assess whether differences could be ruled out. The use of an external blinded 
CVD events adjudication committee eliminated the possibility of bias in the attribution of 
CVD events, and an automated call-in reporting system reduced the likelihood of reporting 
bias for CVD events and SAEs. However, more face-to-face opportunities for tocilizumab-
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treated patients to report AEs directly to study personnel provided an imbalanced sensitivity 
to detecting AEs between arms, which might have contributed to more nonserious safety 
events being reported for patients receiving tocilizumab therapy. The tocilizumab group 
experienced a higher infection rate and a significantly higher rate of gastrointestinal 
perforations. Although both these rates were consistent with rates observed in previous 
tocilizumab clinical trials (29), they do provide additional insight into the comparative safety 
of tocilizumab for RA therapy relative to etanercept. 
 
The limitations of this study include the fact that although the sample size of ENTRACTE was 
larger than in a typical RA trial with a clinical efficacy end point, it was relatively small for a 
trial with a CVD event end point, in part because the eligible RA population is much smaller 
than the diabetes and obesity populations. As such, though it is estimated that the risk for 
MACE in patients treated with tocilizumab is 5% higher than in patients treated with 
etanercept, the uncertainty around this estimate was wide enough that the true risk for 
MACE in the tocilizumab arm could have been anywhere from 43% higher to 23% lower 
than in the etanercept arm. Although the trial did not rule out traditional noninferiority 
margins in the range of 1.30 to 1.33, it did succeed in ruling out the larger 1.8 relative risk 
for MACE in patients receiving tocilizumab compared with those receiving etanercept, as a 
CV safety screening trial, that it was designed to address. Finally, ENTRACTE enrolled an RA 
population remarkable for having both high RA disease activity and elevated CVD risk, which 
may not reflect the characteristics of the average patient with RA in clinical practice. 
Nevertheless, there is biologic reason to believe that the CVD safety of tocilizumab 
compared with that of etanercept can be extrapolated to patients with RA who have lower 
baseline disease activity or lower CVD risk. 
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Additionally, while the drop-out rate for the trial was very low (4%), this rate was similar to 
the overall MACE rate.  Thus, while unlikely, there is potential for even this small amount of 
drop-out to bias the comparison of MACE between the two groups.  Finally, since the trial 
was powered on CV safety, measures of RA disease activity were not collected after 
baseline.  Powering the trial on both CV safety and clinical efficacy would have required the 
enrollment of a much larger sample size than what was feasible. 
 
In summary, the primary results of the ENTRACTE trial provide a framework for assessing 
the comparative CVD safety of tocilizumab with that of etanercept in the setting of 
treatment-associated increases in lipid parameters and in the context of its known clinical 
efficacy and non-CVD safety. 
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FIGURE LEGENDS 
Figure 1. Disposition of ENTRACTE trial participants. The primary end point was time to first 
CV-EAC adjudicated event (CV death, nonfatal MI, or nonfatal stroke) in the ITT population. 
Treatment completers are defined as patients who were not marked as discontinuing from 
randomized treatment before the CSED 30-/90-day window. The early discontinuation from 
randomized treatment count does not include patients who were incorrectly marked as 
discontinuing treatment within the CSED 3-0/90-day window (10 patients). Reasons for 
inclusion in the “Miscellaneous” groups were the following: lost to follow-up, protocol 
violation, noncompliance with study drug, and noncompliance with protocol. Study 
completers were defined as patients who experienced a primary end point or completed 
their final study contact by direct telephone contact or site visit within the CSED 30-/90-day 
window. Only patients who died of non-CV–related causes or who died of CV-related causes 
365 days after the last direct contact (therefore not classified as a primary end point) are 
reported as having discontinued from the study because of death. CSED = common study 
end date; CV = cardiovascular; EAC = cardiovascular events adjudication committee; ETA = 
etanercept; MI = myocardial infarction; TCZ = tocilizumab. 
 
Figure 2. Baseline and change in circulating lipoprotein and triglyceride levels over 216 
weeks: etanercept versus tocilizumab. Medians and interquartile ranges are depicted. ETA = 
etanercept; HDL = high-density lipoprotein; IQR = interquartile range; IV = intravenous; LDL 
= low-density lipoprotein; qw = every week; q4w = every 4 weeks; SC = subcutaneous; TCZ = 
tocilizumab. 
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Table 1. Baseline Characteristics According to Randomized Treatment Allocation (intention-to-treat 
population) 
Baseline Characteristics Etanercept 
n=1542  
Tocilizumab 
n=1538 
Age, years 61±8 61±7 
Male sex, n (%) 340 (22) 345 (22) 
White race, n (%) 1187 (77) 1160 (75) 
Body mass index, kg/m2 (mean ± SD) 29.0±6.0 28.7±5.9 
CVD risk factors 
Current smoking, n (%) 419 (27) 460 (30) 
Hypertension, n (%) 1090 (71) 1098 (71) 
Diabetes, n (%) 284 (18) 259 (17) 
Family history of CVD, n (%) 239 (16) 251 (16) 
Total cholesterol, mg/dL (mean ± SD) 198±42 199±41 
LDL-C, mg/dL (mean ± SD) 113±35 113±35 
HDL-C, mg/dL (mean ± SD) 57±16 57±16 
Triglycerides, mg/dL (interquartile range) 123 (92-168) 123 (94-169) 
Hemoglobin A1C, % (mean ± SD) 5.9±1.1 5.9±1.1 
Current statin use, n (%) 343 (22) 333 (22) 
Previous CVD diagnoses, events, and procedures 
Any previous CVD diagnoses, events, or procedures, n 
(%) 
184 (11.9) 163 (10.6) 
MI, n (%) 79 (5) 67 (4) 
Stroke, n (%) 35 (2) 39 (3) 
Coronary revascularization, n (%) 72 (5) 54 (4) 
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Hospitalized for unstable angina, n (%) 44 (3) 50 (3) 
Symptomatic carotid artery disease, n (%) 14 (1) 7 (1) 
Peripheral arterial disease, n (%) 29 (2) 15 (1) 
RA characteristics 
Duration, years (interquartile range) 7.2 (3.1–4.6) 7.9 (3.1–14.7) 
Rheumatoid factor seropositive, n (%) 1485 (97) 1475 (97) 
Anti-CCP seropositive, n (%) 1139 (90) 1149 (91) 
CRP, mg/L (interquartile range) 10.5 (4.9–23.4) 10.4 (4.8–23.0) 
Any extra-articular RA features, n (%) 465 (30) 462 (30) 
Prior Tumor Necrosis Inhibitor Use, n (%) 41 (2.7%)  33 (2.1%) 
Concurrent RA therapies 
Methotrexate, n (%) 1098 (71) 1111 (72) 
Antimalarials, n (%) 193 (13) 213 (14) 
Sulfasalazine, n (%) 153 (10) 167 (11) 
Leflunomide, n (%) 168 (11) 161 (11) 
Corticosteroids, n (%) 400 (26) 445 (29) 
NSAIDs, n (%) 814 (53) 828 (54) 
CCP = cyclic citrullinated protein; CRP = C-reactive protein; CVD = cardiovascular disease; HDL-C = 
high-density lipoprotein C; LDL-C = low-density lipoprotein C; MI = myocardial infarction; NSAIDs = 
nonsteroidal anti-inflammatory drugs; RA = rheumatoid arthritis; SD = standard deviation. 
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Table 2. Number of first occurrence events and relative hazards (tocilizumab versus etanercept) for primary and secondary end points, exploratory end points, 
and sensitivity analyses  
End Point First Events 
HRb 95% CIf Etanercepta 
   n (%)     events/100 pys (95% CI) 
Tocilizumaba 
n (%)     events/100 pys (95% CI) 
  Primary end point: intention-to-treat populationc 
MACE, including undetermined cause of death, n (%) 78 (5) 1.70 (1.35, 2.10) 83 (5) 1.82 (1.46, 2.24) 1.05 0.77–1.43 
Primary end point: on-treatment populationd 
MACE, including undetermined cause of death, n (%) 52 (3) 1.28 (0.97, 1.66) 57 (4) 1.44 (1.10, 1.85) 1.11 0.76–1.62 
Sensitivity analysis of primary end point:  
intention-to-treat population 
MACE, excluding undetermined cause of death, n (%) 72 (5) 1.57 (1.24, 1.97) 74 (5) 1.63 (1.29, 2.03) 1.01 0.73–1.40 
MACE, before last direct contact, n (%) 46 (3) 1.00 (0.74, 1.33) 49 (3) 1.06 (0.79, 1.40) 1.04 0.70–1.56 
Secondary end points: 
 intention-to-treat population 
Nonfatal MI, n (%) 31 (2) 0.65 (0.45, 0.92) 28 (2) 0.59 (0.40, 0.85) 0.89 0.54–1.49 
Nonfatal and fatal MI, n (%) 32 (2) 0.67 (0.46, 0.95) 29 (2) 0.61 (0.41, 0.87) 0.90 0.54–1.48 
Nonfatal stroke, all types, n (%) 15 (1) 0.33 (0.19, 0.53) 24 (2) 0.49 (0.31, 0.73) 1.53 0.80–2.92 
Nonfatal and fatal stroke, all types, n (%) 16 (1) 0.35 (0.20, 0.56) 26 (2) 0.53 (0.35, 0.78) 1.55 0.83–2.90 
Cardiovascular death, n (%) 35 (2) 0.72 (0.50, 1.00) 36 (2) 0.73 (0.51, 1.02) 1.03 0.64–1.63 
Death from any cause, n (%) 64 (4) 1.31 (1.01, 1.67) 64 (4) 1.31 (1.01, 1.67) 0.99 0.70–1.41 
Expanded composite end point,e n (%) 84 (5) 1.98 (1.61, 2.42) 84 (6) 1.90 (1.53, 2.33) 0.99 0.73–1.34 
Exploratory end points: intention-to-treat population 
MACE + hospitalized heart failure, n (%) 85 (6) 1.90 (1.53, 2.33) 90 (6) 2.12 (1.73, 2.57) 1.05 0.78–1.41 
Hospitalized heart failure, n (%) 8 (1) 0.20 (0.10, 0.38) 12 (1) 0.31 (0.17, 0.50) 1.50 0.61–3.67 
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aEtanercept 50 mg subcutaneous injection weekly; tocilizumab 8 mg/kg intravenous infusion monthly. 
bThe hazard ratio was estimated by Cox regression including treatment (tocilizumab/etanercept) as the only covariate, stratified by previous exposure to anti-TNF therapy and 
history of CV events. Time to event was calculated from (randomization to first event or censoring date + 1)/365.25. 
cPrimary end point is the composite of CV death (including events adjudicated as “undetermined cause of death”), nonfatal myocardial infarction, or nonfatal stroke. Patients not 
experiencing an event were censored at the latest of last date known to be alive, last direct contact, and last indirect contact, capped at the date of last direct contact + 365 days. 
dCensoring date is the latest of last date known to be alive, last direct contact, and last indirect contact, capped at the date of randomized treatment discontinuation or the 
common study end date, whichever is earlier. 
eDefined as the CV composite of the primary end point, with the addition of nonelective coronary revascularization procedures and hospitalization for unstable angina. 
fThe confidence intervals for secondary end points should be viewed only in a descriptive manner because they have not been adjusted for multiplicity. 
CI = confidence interval; CV = cardiovascular; HR = hazard ratio; MACE = major adverse cardiovascular event; MI = myocardial infarction; TNF = tumor necrosis factor.  
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Table 3. Adverse Events: On-Treatment Safety Population 
Adverse Events Etanercept Tocilizumab HR From AG Cox 
Regression Model 
(tocilizumab/etanercept)a 
No. (%) 
With 
Event 
No. of 
Events 
Rate per 
100 Patient-
Years 
No. (%) 
With 
Event 
No. of 
Events 
Rate per 
100 Patient-
Years 
Estimate 95% CI 
General AEs 
AEs leading to withdrawal of study drug 105 (7) 105 2.4 120 (5) 120 2.8 1.15 0.89–1.49 
All SAEs 356 (23) 631 14.4 421 (27) 666 15.7 1.10 0.94–1.28 
AEs of special interest 
Serious infection 111 (7) 139 3.2 159 (10) 190 4.5 1.39 1.08–1.79 
Fatal infection 8 (0.5) 8 0.18 6 (0.4) 6 0.14 0.76 0.26–2.21 
Confirmed gastrointestinal perforation 1 (0.06) 1 0.02 8 (0.5) 8 0.19 8.43 1.06–67.26 
Malignancies (including NMSC) 38 (3) 40 0.9 38 (3) 41 1.0 1.00 0.64–1.58 
Malignancies (excluding NMSC) 27 (2) 28 0.6 29 (2) 30 0.7 1.09 0.64–1.84 
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Significant hypersensitivityb 17 (1) 17 0.4 10 (1) 14 0.3 0.66 0.30–1.46 
Serious hypersensitivityc 7 (0.5) 7 0.2 4 (0.3) 4 0.1 0.61 0.18–2.05 
Serious demyelinating disorders 0 0 0 0 0 0 — — 
Serious bleeding events 13 (1) 17 0.4 19 (1) 20 0.5 1.26 0.61–2.62 
Serious hepatic events 1 (0.06) 1 0 3 (0.2) 3 0.1 2.70 0.31–23.43 
Deep venous thrombosisd 12 (0.8) 12 0.3 9 (0.6) 10 0.2 0.83 0.34-2.03 
Pulmonary embolismd 8 (0.5) 8 0.2 1 (0.1) 1 (0.06) 0.13 0.02-1.04) 
Included are 4373 patient-years in 1542 etanercept-treated patients and 4245 patient-years in 1538 tocilizumab-treated patients.  
aHRs were calculated using the Andersen-Gill Cox regression model for repeated events, including treatment (tocilizumab/etanercept) as the only covariate 
and using the robust sandwich-type estimate of variance. Stratification factors are previous exposure to anti-TNF (yes/no) and history of CV events (yes/no). 
Patients not experiencing an event were censored at last direct contact, capped at the date of treatment discontinuation or the common study end date + 
28 days, whichever was earlier. 
bSignificant hypersensitivity:  All AEs that occurred during or within 24 hours of an infusion or injection and which were not deemed ‘unrelated’ to 
treatment by the investigator, regardless of whether or not they were clinically consistent with hypersensitivity, and led to study treatment discontinuation. 
cSerious hypersensitivity:  All AEs that occurred during or within 24 hours of an infusion or injection and which were not deemed ‘unrelated’ to treatment 
by the investigator, regardless of whether or not they were consistent with hypersensitivity, and were reported as a SAE. 
dDeep venous thrombosis and pulmonary embolism were not pre-defined AEs of special interest in the protocol 
AEs = adverse events; AG = Andersen-Gill; CI = confidence interval; CV = cardiovascular; HR = hazard ratio; NMSC = nonmelanomatous skin cancer; SAEs = 
serious adverse events; TNF = tumor necrosis factor. 
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